Why I bought 850 shares of $BNGO

Daniel purchased 850 shares of BioNano Genomics (BNGO) for approximately £6,000 using inheritance money, pursuing a long-term buy-and-hold strategy focused on emerging industries like genomics, electric vehicles, and plant-based foods rather than mature tech firms.

The investment outlook is influenced by BioNano Genomics's Saphyr system, sector valuation dynamics, and speculation regarding potential inclusion in Cathie Wood's ARK Invest ETFs.

Investment potential of emerging sectors versus mature technology firms at different points on the adoption S-curve.

Anticipated market shifts toward electric vehicles following government combustion-engine sales bans and plant-based foods to lower emissions.

Valuations of genome editing companies, comparing earlier pricing of CRISPR to the current share price of BNGO.

Capabilities and medical potential of genomic sequencing and gene therapy technology, including the Saphyr system.

Influence of Cathie Wood's ETF additions on retail investor sentiment and stock price surges, citing Palantir and DraftKings.

Daniel purchased 850 shares of BioNano Genomics (BNGO) for approximately £6,000 using inheritance money.

BNGO share prices rose from approximately $4 or $5 to about $11 in January.

Cathie Wood purchased shares of Palantir and DraftKings, while selling off shares of CRISPR.

Whether BNGO will reach price targets such as $40 by March or April or $80 by the end of the year.

Whether Cathie Wood will add BNGO to the ARK Invest ETFs.

Whether Daniel will buy additional shares of BNGO if the price dips to expand the position to 1,000 shares.